ClinicalTrials.gg
CompletedNCT03383302STILEUpdated Jul 17, 2026Results posted

SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects

A Phase 1/2 interventional study of Stereotactic body radiotherapy and Nivolumab in Non-small Cell Lung Cancer Stage II and Non-small Cell Lung Cancer Stage I, sponsored by Royal Marsden NHS Foundation Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Royal Marsden NHS Foundation Trust · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 43 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
74th of 120
36 · median 66
Started
2018
with 14 others
Phase 1/2
12 of 120
2 open now
Registered
56th of 120
by date

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 74th largest by enrollment, is one of 15 that started in 2018, is one of 12 in phase 1/2, and was the 56th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a single arm, multi-centre, phase II open label study of nivolumab with stereotactic body radiotherapy (SBRT) for early stage non-small cell lung cancer.

SBRT will be delivered in either 3 or 5 fractions for peripheral disease or 8 fractions in central disease. A flat dose of 240 mg nivolumab infusion will begin after the final fraction of SBRT, within 24 hours and typically on the same day. Nivolumab will subsequently be given every 2 weeks at a flat dose of 240 mg for a further 13 cycles followed by Nivolumab 480mg Q4W for 7 cycles until 20 cycles in total are complete, unless any study drug discontinuation criteria are met. Treatment (20 cycles) will take a minimum of 1 year to complete but may exceed this timeframe if treatment delays are encountered.

(Patients who have enrolled on Nivolumab Q2W 240mg regimen for 26 cycles and are beyond cycle 14 will receive 26 cycles Q2W in total to complete treatment).

Assessment of toxicities will be performed at each clinic visit during treatment, at 30 days after the final nivolumab infusion and until 100 days after the final nivolumab infusion. Changes in spirometry values and PFTs will be assessed throughout the trial.

Relapse rates will be assessed with staging CT scans at 3, 6, 12, 18 and 24 months post SBRT.

An exploratory assessment will be made of the effect pre-treatment pulmonary function tests (PFTs) have on outcome measures.

Read the detailed description

This is a single arm, multi-centre, phase II open label study of nivolumab with stereotactic body radiotherapy (SBRT) for early stage non-small cell lung cancer.

Current United Kingdom (UK) guidelines for SBRT do not specify exclusion pulmonary function criteria. Severely reduced Forced Expiratory Volume in 1 second (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO) (\<40% predicted) are common reasons for medical inoperability leading to the choice of SBRT. In a large prospective study of patients undergoing SBRT, poor baseline PFT was not predictive of toxicity including pneumonitis. At the 2 year follow up, the mean decline in percentage of predicted forced expiratory volume in one second (FEV1) and diffusion capacity of carbon monoxide (DLCO) were only 5.8% and 6.3% respectively. Focal SBRT is a well-tolerated procedure and acute complications are generally transient. Symptomatic radiation pneumonitis has been reported at rates of 4-25% of patients.

Drug induced pneumonitis is reported at 6% in lung cancer patients receiving nivolumab and at 2% with grade 3-4 toxicity. Of note, such rates are similar or lower to other drugs used in NSCLC including docetaxel for which no PFT restrictions occur. In this study, frequent assessment of spirometry values may help to predict patients that are developing subclinical pneumonitis and prompt for early intervention.

SBRT will be delivered in either 3 or 5 fractions for peripheral disease or 8 fractions in central disease. A flat dose of 240 mg nivolumab infusion will begin after the final fraction of SBRT, within 24 hours and typically on the same day. Nivolumab will subsequently be given every 2 weeks at a flat dose of 240 mg for a further 13 cycles followed by Nivolumab 480mg Q4W for 7 cycles until 20 cycles in total are complete, unless any study drug discontinuation criteria are met. The study will recruit 31 patients. We anticipate it will take approximately 18 months to recruit 31 patients.

The study will include subjects with histologically verified NSCLC deemed by a local multidisciplinary team (MDT) to have anatomical stage T1-3 [≤6cm] N0 M0 by means of computed tomography (CT) and fludeoxyglucose-positron emission tomography (FDG-PET) , amenable to radical treatment with SBRT and inoperable due to medical co-morbidity, being technically unresectable or patient declining surgery after offer of surgical assessment.

Subjects will receive nivolumab as per the treatment schedule unless any withdrawal criteria are met. The first nivolumab infusion will be given after the final fraction of SBRT, within 24 hours and generally on the same day. Clinical follow up and investigations are as detailed in the schedule of assessment.

The first 5 patients to enroll must have Eastern Co-operative Oncology Group (ECOG) performance status (PS) \< 2 at the time of first dose of investigational medical product (IMP). An Independent Data Monitoring Committee (IDMC) will meet when the first 5 patients have reached 3 months follow up from their 1st dose of nivolumab or have withdrawn consent to follow-up. Patients that have enrolled but did not receive IMP will be replaced. The IDMC, if satisfied with the safety data from the initial 5 patients, may recommend escalation to include recruitment of patients with ECOG performance status of 2. Further patients of PS \<2 may enroll while awaiting the outcome of the IDMC meeting.

The IDMC will perform a further safety review when the first 5 patients enrolled with ECOG performance status 2 have reached 3 months follow up from their final fraction of radiotherapy or have withdrawn consent to follow-up. Patients that have enrolled but did not receive IMP will be replaced. Further patients with ECOG performance status 2 will not be able to enroll unless recommendation is given by the IDMC. In the event that 5 PS 2 patients have not enrolled by the point that the 15th recruited patient has reached 3 months follow up, then there will be a further mandated IDMC meeting to assess safety data from the study. Patients may continue to enroll while awaiting the outcome of this IDMC meeting.

Assessment of toxicities will be performed at each clinic visit during treatment, at 30 days after the final nivolumab infusion and until 100 days after the final nivolumab infusion. Changes in spirometry values and PFTs will be assessed throughout the trial.

Relapse rates will be assessed with staging CT scans at 3, 6, 12, 18 and 24 months post SBRT.

An exploratory assessment will be made of the effect pre-treatment pulmonary function tests (PFTs) have on outcome measures.

03

Conditions studied

  • Non-small Cell Lung Cancer Stage II
  • Non-small Cell Lung Cancer Stage I

Keywords

  • Non-small cell lung cancer
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have signed and dated a Research Ethics Committee (REC) approved written form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care
  • Subjects must be willing and able to comply with scheduled visits, treatment schedule, and laboratory tests
  • Performance status (PS) 0-2
  • Minimum of first 5 patients to be PS 0-1
  • PS 2 patients to be enrolled only following recommendation by the Independent Data Monitoring Committee (IDMC)
  • Patients with histological diagnosis of NSCLC, all histological sub-types are eligible
  • Not suitable for surgery because of medical co-morbidity, lesion is technically inoperable or patient declines surgery after surgical assessment (or option of assessment)
  • Single or synchronous/metachronous primary NSCLC lesions, tumour stage T1-3 (≤6cm), N0 M0 (UICC v.8) as determined by the local MDT based on minimum investigations of CT chest/abdomen within 8 weeks and FDG-PET within 6 weeks of 1st fraction of SBRT. Where the radiological nodal status is equivocal then only eligible if possible nodal disease is subsequently confirmed as pathologically negative with mediastinoscopy or endoscopic bronchial or oesophageal ultra-sound as necessary
  • For synchronous tumours one lesion must have a histological diagnosis of NSCLC. For the other lesion a radiological diagnosis of NSCLC as determined by lung MDT is sufficient. (Upon diagnosis of metachronous primary NSCLC these lesions require biopsy for trial entry)
  • Metachronous (single) primary NSCLC lesions, tumour stage T1-3 (≤6cm) N0 M0 (UICC v.8) presenting after previous treatment of T1-3(≤6cm) N0 M0 (UICC v.8) with surgery or SBRT are eligible for inclusion. Lung constraints must be able to feasibly achieved (according to dose constraints in 7.1.2
  • Tumour stage T1-3 termed as 'central' disease within 2cm of main airways and proximal bronchial tree, but not abutting these structures (ultra-central), are suitable for entry. Up to 5 patients with 'central' primary NSCLC (up to 2 lesions) can be enrolled and followed up for 3 months following their final fraction of radiotherapy at which stage an IDMC meeting is required to assess further 'central' primary NSCLC recruitment
  • Screening laboratory values must meet the following criteria prior to commencement of treatment:

    i) WBCs ≥ 2000/μL ii) Neutrophils ≥1500/μL iii) ≥ 100 X10³/μL iv) ≥ 9.0 g/dL v) Serum creatinine of ≤ 1.5 X or (CrCl)/ (GFR) > 40 mL/minute (using Cockcroft/Gault formula or as assessed by local practice)

    1. . Female CrCl= [(140- age in years) X weight in kg X 0.85) ÷ (72 X serum creatinine in mg/ dL)]
    2. . Male CrCl= [(140- age in years) X weight in kg X 1.00) ÷ (72 X serum creatinine in mg/ dL)] vi) ≤ 3 X ULN vii) ALT ≤ 3 X ULN viii) Total ≤ 1.5 X ULN (except subjects with Gilbert Syndrome, who must have total bilirubin \< 50 μmol/L)
  • No prior adjuvant or foreseen or adjuvant chemotherapy is allowed
  • Males and Females ≥ 18 years of age
  • Women of (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) in the screening period and within 24 hours prior to the start of study drug.
  • Women must not be breastfeeding during the study treatment and for a period up to 23 weeks post treatment completion
  • WOCBP must agree to follow instructions for method(s) of during the study treatment and for a total of 23 weeks post treatment completion
  • Males who are sexually active with WOCBP must agree to follow instructions for method(s) for contraception for a total of 31 weeks post treatment completion.

Exclusion criteria

Exclusion Criteria:

  • Any tumour that is not clinically definable on the treatment planning CT scan e.g. surrounded by consolidation or atelectasis
  • 'Ultra-central' tumours, i.e. those adjacent to the hilar structures, with the gross tumour volume directly abutting a main bronchus
  • Subjects with active, known disease. Subjects with Type I diabetes mellitus, residual hypothyroidism due to an autoimmune condition requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enrol.
  • Subjects with a condition requiring systemic treatment with either (> 10 mg daily prednisone equivalent) or other medications within 14 days of the first dose of study drug administration. Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease
  • Subjects with previous (except non-melanoma skin cancers, early stage NSCLC treated with SBRT or surgery and current lesion not considered to be NSCLC, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period
  • Patient with known interstitial lung disease or active, non-infectious pneumonitis
  • Previous conventional radiotherapy to the chest or mediastinum. Patients who have had previous breast radiotherapy may be eligible at the discretion of the Chief Investigator
  • Any serious or uncontrolled medical disorder or active infection that, in the opinion of the Investigator, may increase the risk associated with study participation, study drug administration, or would impair the ability of the subject to receive protocol therapy
  • All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must have resolved to Grade 1 ( v.4.0) or baseline before administration of study drug
  • Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatment
  • Subjects who received prior therapy with , anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) or who have previously taken part in a randomized BMS clinical trial for nivolumab or ipilimumab
  • Known history of testing positive for (HIV) or known acquired immunodeficiency syndrome (AIDS)
  • Positive test for virus (HBV) using HBV surface antigen (HBVsAg) test or positive test for virus (HCV) using HCV ribonucleic acid (RNA) or HCV antibody test indicating acute or chronic infection

    o Patients with a positive HCV antibody but no detection of HCV RNA indicating no current infection are eligible

  • Patients who have received a within 30 days prior to the first dose of trial treatment
  • History of allergy to study drug components
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Arm 1 Tolerabilty

    This is a single arm study of nivolumab administered on completion of stereotactic body radiotherapy (SBRT) to patients with early stage NSCLC. The first 5 patients to enroll must have Eastern Co-operative Oncology Group (ECOG) performance status \< 2 at the time of first dose of investigational medical product (IMP). An Independent Data Monitoring Committee (IDMC) will meet when the first 5 patients have reached 3 months follow up from their 1st dose of nivolumab or have withdrawn consent to follow-up. The IDMC, if satisfied with the safety data from the initial 5 patients, may recommend escalation to include recruitment of patients with ECOG performance status of 2.

    Radiation: Stereotactic body radiotherapy · Drug: Nivolumab

Interventions

  • RadiationStereotactic body radiotherapy

    Patients will receive a total of 54 Gy if delivered in 3 fractions, 55 Gy if delivered in 5 fractions or 60 Gy if delivered in 8 fractions.

    Also known as: SBRT

  • Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody, that binds to the PD-1 receptor and blocks interaction with its ligands PD-L1 and PD-L2. Nivolumab will be administered intravenously at a flat dose of 240 mg q2w over 30 minutes for 13 cycles followed by 480mg q4w over 60 minutes for 7 cycles, until 20 cycles in total to complete (a minimum of 1 year of treatment if no delays are encountered).

    Also known as: L01XC17, Opdivo

06

What researchers measure

Primary outcomes

  1. Assessment of Lung Toxicity (Pneumonitis) From Treatment With Nivolumab After SBRT for Early Stage NSCLC

    Number of participants with grade ≥ 3 pneumonitis from treatment with nivolumab after stereotactic body radiotherapy (SBRT) within 6 months of the final fraction of SBRT (2-3 weeks treatment duration depending on dosing). A rate that exceeds 20% will be deemed unacceptable and will lead to a rejection of the null hypothesis.

    Time frame: Six months from final dose of SBRT (2-3 weeks) administered for each patient

Secondary outcomes

  1. Adverse Events (Toxicity) by Worst Grade

    Rates of toxicity will be summarised as worst toxicity grade during treatment as per CTCAE v. 4 after treatment with Nivolumab following SBRT.

    Time frame: 24 months from last dose of SBRT (2-3 weeks treatment duration)

  2. Proportion of Patient Receiving 1,2,3,4,5 and 6 Doses of Nivolumab Within 16 Weeks of Commencing Adjuvant Nivolumab After SBRT for Early Stage NSCLC

    The proportion of patients receiving 1,2,3,4,5 and 6 doses within 16 weeks of commencing treatment are reported with a 95% exact confidence interval.

    Time frame: Within 16 weeks of each patient commencing treatment with Nivolumab after SBRT (2-3 weeks duration)

  3. Disease Relapse - To Assess Local, Local-regional and Distant Disease Relapse Rates

    All rates of relapse (local, loco-regional and distant rates) were evaluated using the 30 patients in the efficacy population and presented as a proportion with a 95% exact binomial confidence interval. Time to event analysis was not performed within these endpoints as the number of events were too low.

    Time frame: 24 months from last dose of SBRT (2-3 weeks duration)

  4. Overall Survival

    Overall survival (OS) was evaluated for 29 out of the 31 patients in the efficacy population (1 patient withdrew during SBRT and no SBRT start date was recorded) OS rates at 12 and 24 months are reported.

    Time frame: Overall survival rate (OS) at 12 and 24 months

  5. Disease Free Survival

    Disease-free survival (DFS) was evaluated for 29 out of the 31 patients in the efficacy population (1 patient withdrew during SBRT and no SBRT start date was recorded) DFS rates at 6, 12 and 24 months are reported.

    Time frame: Disease Free Survival (DFS) at 6, 12 and 24 months

  6. Health-related Quality of Life (HRQoL) Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) in Patients Treated With Nivolumab After SBRT for Early Stage NSCLC

    Estimation of the health-related quality of life (HRQoL) score at each time point of analysis (screening, then at 3, 6, 9, 12, 18, 24 months post-SBRT). QOL questionnaires will be scored according to the EORTC Quality of Life Questionnaire (QLQ-C30) version 3 scoring manual. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level, in cases of a functioning scale a better outcome, but for symptom scales a higher score represents a worse outcome.

    Time frame: 24 months from last dose of SBRT (2-3 weeks duration)

  7. HRQoL Using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) in Patients Treated With Nivolumab After SBRT for Early Stage NSCLC.

    Estimation of HRQoL in patients treated with Nivolumab after SBRT for early stage NSCLC using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at each time point of analysis (screening, then at 3, 6, 9, 12, 18, 24 months post-SBRT). QOL data will be scored according to the QLQ-LC13 scoring manual, which includes one multi-item scale to assess dyspnea, and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and haemoptysis, all had a score ranging from 0 to 100, where a higher score represents a high level of symptomatology/problems.

    Time frame: 24 months from last dose of SBRT (2-3 weeks)

07

Results

Posted Jul 17, 2026

Participant flow

Thirty-six patients were registered into the study from the Royal Marsden site between February 2018 and January 2024. However, only 31 were eligible and of which 29 started study treatment.

Participant flow — Overall Study
MilestoneArm 1 Tolerability
Started31
Received sbrt treatment30
Received nivolumab treatment (primary analysis population)29
Completed study treatment6
Completed20
Not completed11
Withdrew: Death4
Withdrew: Deterioration in health2
Withdrew: Withdrawal by subject1
Withdrew: Lost to follow-up4

Outcome measures

PrimaryAssessment of Lung Toxicity (Pneumonitis) From Treatment With Nivolumab After SBRT for Early Stage NSCLC

Number of participants with grade ≥ 3 pneumonitis from treatment with nivolumab after stereotactic body radiotherapy (SBRT) within 6 months of the final fraction of SBRT (2-3 weeks treatment duration depending on dosing). A rate that exceeds 20% will be deemed unacceptable and will lead to a rejection of the null hypothesis.

Time frame:
Six months from final dose of SBRT (2-3 weeks) administered for each patient
Reported as:
Count of participants · Participants
Assessment of Lung Toxicity (Pneumonitis) From Treatment With Nivolumab After SBRT for Early Stage NSCLC
ParticipantsArm 1 Tolerabilty
Assessment of Lung Toxicity (Pneumonitis) From Treatment With Nivolumab After SBRT for Early Stage NSCLC0
SecondaryAdverse Events (Toxicity) by Worst Grade

Rates of toxicity will be summarised as worst toxicity grade during treatment as per CTCAE v. 4 after treatment with Nivolumab following SBRT.

Time frame:
24 months from last dose of SBRT (2-3 weeks treatment duration)
Reported as:
Count of participants · Participants
Adverse Events (Toxicity) by Worst Grade
ParticipantsArm 1 Tolerabilty
Grade 11
Grade 211
Grade 316
Grade 41
SecondaryProportion of Patient Receiving 1,2,3,4,5 and 6 Doses of Nivolumab Within 16 Weeks of Commencing Adjuvant Nivolumab After SBRT for Early Stage NSCLC

The proportion of patients receiving 1,2,3,4,5 and 6 doses within 16 weeks of commencing treatment are reported with a 95% exact confidence interval.

Time frame:
Within 16 weeks of each patient commencing treatment with Nivolumab after SBRT (2-3 weeks duration)
Reported as:
Number · proportion of participants
Proportion of Patient Receiving 1,2,3,4,5 and 6 Doses of Nivolumab Within 16 Weeks of Commencing Adjuvant Nivolumab After SBRT for Early Stage NSCLC
proportion of participantsArm 1 Tolerabilty
Received 1 dose1.00 (0.88 to 1.00)
Received 2 doses0.90 (0.73 to 0.98)
Received 3 doses0.83 (0.64 to 0.94)
Received 4 doses0.79 (0.60 to 0.92)
Received 5 doses0.79 (0.60 to 0.92)
Received 6 doses0.76 (0.56 to 0.90)
SecondaryDisease Relapse - To Assess Local, Local-regional and Distant Disease Relapse Rates

All rates of relapse (local, loco-regional and distant rates) were evaluated using the 30 patients in the efficacy population and presented as a proportion with a 95% exact binomial confidence interval. Time to event analysis was not performed within these endpoints as the number of events were too low.

Time frame:
24 months from last dose of SBRT (2-3 weeks duration)
Reported as:
Number · Proportion of participants
Disease Relapse - To Assess Local, Local-regional and Distant Disease Relapse Rates
Proportion of participantsArm 1 Tolerabilty
Local relapse0.03 (0.001 to 0.17)
Loco-regional relapse0.03 (0.001 to 0.17)
Distant relapse0.07 (0.01 to 0.22)
Any relapse0.13 (0.04 to 0.31)
SecondaryOverall Survival

Overall survival (OS) was evaluated for 29 out of the 31 patients in the efficacy population (1 patient withdrew during SBRT and no SBRT start date was recorded) OS rates at 12 and 24 months are reported.

Time frame:
Overall survival rate (OS) at 12 and 24 months
Reported as:
Number · Percentage of participants
Overall Survival
Percentage of participantsArm 1 Tolerabilty
12 month OS rate100 (NA to NA)
24 month OS rate89 (70 to 96)
SecondaryDisease Free Survival

Disease-free survival (DFS) was evaluated for 29 out of the 31 patients in the efficacy population (1 patient withdrew during SBRT and no SBRT start date was recorded) DFS rates at 6, 12 and 24 months are reported.

Time frame:
Disease Free Survival (DFS) at 6, 12 and 24 months
Reported as:
Number · percentage of participants
Disease Free Survival
percentage of participantsArm 1 Tolerabilty
6 month DFS97 (78 to 99)
12 month DFS93 (75 to 98)
24 month DFS85 (65 to 94)
SecondaryHealth-related Quality of Life (HRQoL) Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) in Patients Treated With Nivolumab After SBRT for Early Stage NSCLC

Estimation of the health-related quality of life (HRQoL) score at each time point of analysis (screening, then at 3, 6, 9, 12, 18, 24 months post-SBRT). QOL questionnaires will be scored according to the EORTC Quality of Life Questionnaire (QLQ-C30) version 3 scoring manual. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level, in cases of a functioning scale a better outcome, but for symptom scales a higher score represents a worse outcome.

Time frame:
24 months from last dose of SBRT (2-3 weeks duration)
Reported as:
Median · score on a scale
Health-related Quality of Life (HRQoL) Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) in Patients Treated With Nivolumab After SBRT for Early Stage NSCLC
score on a scaleArm 1 Tolerabilty
EORTC QLQ-C30 Global Health Status: Screening67 (33 to 100)
EORTC QLQ-C30 Global Health Status: 3 months PSBRT67 (25 to 100)
EORTC QLQ-C30 Global Health Status: 6 months PSBRT63 (0 to 100)
EORTC QLQ-C30 Global Health Status: 9 months PSBRT67 (0 to 100)
EORTC QLQ-C30 Global Health Status: 12 months PSBRT67 (17 to 100)
EORTC QLQ-C30 Global Health Status: 15 months PSBRT67 (25 to 100)
EORTC QLQ-C30 Global Health Status: 18 months PSBRT58 (17 to 100)
EORTC QLQ-C30 Global Health Status: 24 months PSBRT67 (17 to 100)
EORTC QLQ-C30 Physical functioning: Screening80 (53 to 100)
EORTC QLQ-C30 Physical functioning: 3 month PSBRT80 (40 to 100)
EORTC QLQ-C30 Physical functioning: 6 month PSBRT73 (13 to 100)
EORTC QLQ-C30 Physical functioning: 9 month PSBRT67 (13 to 100)
EORTC QLQ-C30 Physical functioning: 12 month PSBRT70 (13 to 100)
EORTC QLQ-C30 Physical functioning: 15 month PSBRT53 (27 to 100)
EORTC QLQ-C30 Physical functioning: 18 month PSBRT80 (7 to 100)
EORTC QLQ-C30 Physical functioning: 24 month PSBRT73 (13 to 100)
EORTC QLQ-C30 Role functioning: Screening83 (0 to 100)
EORTC QLQ-C30 Role functioning: 3 months PSBRT83 (33 to 100)
EORTC QLQ-C30 Role functioning: 6 months PSBRT67 (0 to 100)
EORTC QLQ-C30 Role functioning: 9 months PSBRT83 (17 to 100)
EORTC QLQ-C30 Role functioning: 12 months PSBRT67 (0 to 100)
EORTC QLQ-C30 Role functioning: 15 months PSBRT67 (0 to 100)
EORTC QLQ-C30 Role functioning: 18 months PSBRT67 (0 to 100)
EORTC QLQ-C30 Role functioning: 24 months PSBRT20 (0 to 100)
EORTC QLQ-C30 Emotional functioning: Screening92 (33 to 100)
EORTC QLQ-C30 Emotional functioning: 3 month PSBRT92 (25 to 100)
EORTC QLQ-C30 Emotional functioning: 6 month PSBRT83 (0 to 100)
EORTC QLQ-C30 Emotional functioning: 9 month PSBRT83 (42 to 100)
EORTC QLQ-C30 Emotional functioning: 12 month PSBRT75 (0 to 100)
EORTC QLQ-C30 Emotional functioning: 15 month PSBRT75 (0 to 100)
EORTC QLQ-C30 Emotional functioning: 18 month PSBRT75 (17 to 100)
EORTC QLQ-C30 Emotional functioning: 24 month PSBRT75 (8 to 100)
EORTC QLQ-C30 Cognitive functioning: Screening83 (50 to 100)
EORTC QLQ-C30 Cognitive functioning: 3 month PSBRT92 (33 to 100)
EORTC QLQ-C30 Cognitive functioning: 6 month PSBRT83 (0 to 100)
EORTC QLQ-C30 Cognitive functioning: 9 month PSBRT83 (33 to 100)
EORTC QLQ-C30 Cognitive functioning: 12 month PSBRT83 (17 to 100)
EORTC QLQ-C30 Cognitive functioning: 15 month PSBRT83 (0 to 100)
EORTC QLQ-C30 Cognitive functioning: 18 month PSBRT75 (17 to 100)
EORTC QLQ-C30 Cognitive functioning: 24 month PSBRT67 (17 to 100)
EORTC QLQ-C30 Social functioning: Screening92 (33 to 100)
EORTC QLQ-C30 Social functioning: 3 month PSBRT83 (0 to 100)
EORTC QLQ-C30 Social functioning: 6 month PSBRT75 (33 to 100)
EORTC QLQ-C30 Social functioning: 9 month PSBRT83 (17 to 100)
EORTC QLQ-C30 Social functioning: 12 month PSBRT67 (0 to 100)
EORTC QLQ-C30 Social functioning: 15 month PSBRT83 (0 to 100)
EORTC QLQ-C30 Social functioning: 18 month PSBRT67 (17 to 100)
EORTC QLQ-C30 Social functioning: 24 month PSBRT67 (0 to 100)
EORTC QLQ-C30 Fatigue: Screening22 (0 to 56)
EORTC QLQ-C30 Fatigue: 3 month PSBRT22 (0 to 78)
EORTC QLQ-C30 Fatigue: 6 month PSBRT33 (0 to 100)
EORTC QLQ-C30 Fatigue: 9 month PSBRT22 (0 to 89)
EORTC QLQ-C30 Fatigue: 12 month PSBRT33 (0 to 100)
EORTC QLQ-C30 Fatigue: 15 month PSBRT33 (0 to 100)
EORTC QLQ-C30 Fatigue: 18 month PSBRT33 (0 to 67)
EORTC QLQ-C30 Fatigue: 24 month PSBRT44 (0 to 78)
EORTC QLQ-C30 Nausea and vomiting: Screening0 (0 to 17)
EORTC QLQ-C30 Nausea and vomiting: 3 month PSBRT0 (0 to 33)
EORTC QLQ-C30 Nausea and vomiting: 6 month PSBRT0 (0 to 67)
EORTC QLQ-C30 Nausea and vomiting: 9 month PSBRT0 (0 to 17)
EORTC QLQ-C30 Nausea and vomiting: 12 month PSBRT0 (0 to 50)
EORTC QLQ-C30 Nausea and vomiting: 15 month PSBRT0 (0 to 50)
EORTC QLQ-C30 Nausea and vomiting: 18 month PSBRT0 (0 to 33)
EORTC QLQ-C30 Nausea and vomiting: 24 month PSBRT0 (0 to 33)
EORTC QLQ-C30 Pain: Screening0 (0 to 67)
EORTC QLQ-C30 Pain: 3 month PSBRT0 (0 to 83)
EORTC QLQ-C30 Pain: 6 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Pain: 9 month PSBRT17 (0 to 100)
EORTC QLQ-C30 Pain: 12 month PSBRT33 (0 to 100)
EORTC QLQ-C30 Pain: 15 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Pain: 18 month PSBRT17 (0 to 83)
EORTC QLQ-C30 Pain: 24 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Dyspnea: Screening33 (0 to 100)
EORTC QLQ-C30 Dyspnea: 3 month PSBRT33 (0 to 33)
EORTC QLQ-C30 Dyspnea: 6 month PSBRT33 (0 to 100)
EORTC QLQ-C30 Dyspnea: 9 month PSBRT33 (0 to 100)
EORTC QLQ-C30 Dyspnea: 12 month PSBRT33 (0 to 100)
EORTC QLQ-C30 Dyspnea: 15 month PSBRT33 (0 to 100)
EORTC QLQ-C30 Dyspnea: 18 month PSBRT33 (0 to 100)
EORTC QLQ-C30 Dyspnea: 24 month PSBRT33 (0 to 100)
EORTC QLQ-C30 Insomnia: Screening0 (0 to 100)
EORTC QLQ-C30 Insomnia: 3 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Insomnia: 6 month PSBRT33 (0 to 100)
EORTC QLQ-C30 Insomnia: 9 month PSBRT33 (0 to 100)
EORTC QLQ-C30 Insomnia: 12 month PSBRT33 (0 to 100)
EORTC QLQ-C30 Insomnia: 15 month PSBRT33 (0 to 100)
EORTC QLQ-C30 Insomnia: 18 month PSBRT17 (0 to 67)
EORTC QLQ-C30 Insomnia: 24 month PSBRT33 (0 to 100)
EORTC QLQ-C30 Appetite Loss: Screening0 (0 to 67)
EORTC QLQ-C30 Appetite Loss: 3 month PSBRT0 (0 to 67)
EORTC QLQ-C30 Appetite Loss: 6 month PSBRT33 (0 to 100)
EORTC QLQ-C30 Appetite Loss: 9 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Appetite Loss: 12 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Appetite Loss: 15 month PSBRT33 (0 to 100)
EORTC QLQ-C30 Appetite Loss: 18 month PSBRT0 (0 to 67)
EORTC QLQ-C30 Appetite Loss: 24 month PSBRT0 (0 to 67)
EORTC QLQ-C30 Constipation: Screening0 (0 to 67)
EORTC QLQ-C30 Constipation: 3 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Constipation: 6 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Constipation: 9 month PSBRT0 (0 to 33)
EORTC QLQ-C30 Constipation: 12 month PSBRT0 (0 to 67)
EORTC QLQ-C30 Constipation: 15 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Constipation: 18 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Constipation: 24 month PSBRT0 (0 to 67)
EORTC QLQ-C30 Diarrhea: Screening0 (0 to 33)
EORTC QLQ-C30 Diarrhea: 3 month PSBRT0 (0 to 67)
EORTC QLQ-C30 Diarrhea: 6 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Diarrhea: 9 month PSBRT0 (0 to 67)
EORTC QLQ-C30 Diarrhea: 12 month PSBRT0 (0 to 67)
EORTC QLQ-C30 Diarrhea: 15 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Diarrhea: 18 month PSBRT0 (0 to 67)
EORTC QLQ-C30 Diarrhea: 24 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Financial Difficulties: Screening0 (0 to 67)
EORTC QLQ-C30 Financial Difficulties: 3 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Financial Difficulties: 6 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Financial Difficulties: 9 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Financial Difficulties: 12 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Financial Difficulties: 15 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Financial Difficulties: 18 month PSBRT0 (0 to 100)
EORTC QLQ-C30 Financial Difficulties: 24 month PSBRT0 (0 to 67)
SecondaryHRQoL Using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) in Patients Treated With Nivolumab After SBRT for Early Stage NSCLC.

Estimation of HRQoL in patients treated with Nivolumab after SBRT for early stage NSCLC using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at each time point of analysis (screening, then at 3, 6, 9, 12, 18, 24 months post-SBRT). QOL data will be scored according to the QLQ-LC13 scoring manual, which includes one multi-item scale to assess dyspnea, and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and haemoptysis, all had a score ranging from 0 to 100, where a higher score represents a high level of symptomatology/problems.

Time frame:
24 months from last dose of SBRT (2-3 weeks)
Reported as:
Median · score on a scale
HRQoL Using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) in Patients Treated With Nivolumab After SBRT for Early Stage NSCLC.
score on a scaleArm 1 Tolerabilty
EORTC QLQ-LC13 Dyspnea: Screening22 (0 to 56)
EORTC QLQ-LC13 Dyspnea: 3 month PSBRT22 (0 to 89)
EORTC QLQ-LC13 Dyspnea: 6 month PSBRT22 (0 to 100)
EORTC QLQ-LC13 Dyspnea: 9 month PSBRT33 (0 to 67)
EORTC QLQ-LC13 Dyspnea: 12 month PSBRT33 (0 to 89)
EORTC QLQ-LC13 Dyspnea: 15 month PSBRT22 (0 to 89)
EORTC QLQ-LC13 Dyspnea: 18 month PSBRT33 (0 to 67)
EORTC QLQ-LC13 Dyspnea: 24 month PSBRT33 (0 to 78)
EORTC QLQ-LC13 Coughing: Screening33 (0 to 67)
EORTC QLQ-LC13 Coughing: 3 month PSBRT33 (0 to 100)
EORTC QLQ-LC13 Coughing: 6 month PSBRT33 (0 to 100)
EORTC QLQ-LC13 Coughing: 9 month PSBRT33 (0 to 100)
EORTC QLQ-LC13 Coughing: 12 month PSBRT33 (0 to 100)
EORTC QLQ-LC13 Coughing: 15 month PSBRT33 (0 to 67)
EORTC QLQ-LC13 Coughing: 18 month PSBRT33 (0 to 100)
EORTC QLQ-LC13 Coughing: 24 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Haemoptysis: Screening0 (0 to 100)
EORTC QLQ-LC13 Haemoptysis: 3 month PSBRT0 (0 to 33)
EORTC QLQ-LC13 Haemoptysis: 6 month PSBRT0 (0 to 33)
EORTC QLQ-LC13 Haemoptysis: 9 month PSBRT0 (0 to 0)
EORTC QLQ-LC13 Haemoptysis: 12 month PSBRT0 (0 to 33)
EORTC QLQ-LC13 Haemoptysis: 15 month PSBRT0 (0 to 0)
EORTC QLQ-LC13 Haemoptysis: 18 month PSBRT0 (0 to 0)
EORTC QLQ-LC13 Haemoptysis: 24 month PSBRT0 (0 to 33)
EORTC QLQ-LC13 Sore mouth: Screening0 (0 to 33)
EORTC QLQ-LC13 Sore mouth: 3 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Sore mouth: 6 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Sore mouth: 9 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Sore mouth: 12 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Sore mouth: 15 month PSBRT0 (0 to 0)
EORTC QLQ-LC13 Sore mouth: 18 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Sore mouth: 24 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Dysphagia: Screening0 (0 to 33)
EORTC QLQ-LC13 Dysphagia: 3 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Dysphagia: 6 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Dysphagia: 9 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Dysphagia: 12 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Dysphagia: 15 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Dysphagia: 18 month PSBRT0 (0 to 33)
EORTC QLQ-LC13 Dysphagia: 24 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Peripheral neuropathy: Screening0 (0 to 67)
EORTC QLQ-LC13 Peripheral neuropathy: 3 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Peripheral neuropathy: 6 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Peripheral neuropathy: 9 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Peripheral neuropathy: 12 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Peripheral neuropathy: 15 month PSBRT17 (0 to 67)
EORTC QLQ-LC13 Peripheral neuropathy: 18 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Peripheral neuropathy: 24 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Alopecia: Screening0 (0 to 100)
EORTC QLQ-LC13 Alopecia: 3 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Alopecia: 6 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Alopecia: 9 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Alopecia: 12 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Alopecia: 15 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Alopecia: 18 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Alopecia: 24 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Pain in the chest: Screening0 (0 to 67)
EORTC QLQ-LC13 Pain in the chest: 3 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Pain in the chest: 6 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Pain in the chest: 9 month PSBRT0 (0 to 33)
EORTC QLQ-LC13 Pain in the chest: 12 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Pain in the chest: 15 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Pain in the chest: 18 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Pain in the chest: 24 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Pain in the arm/shoulder: Screening0 (0 to 100)
EORTC QLQ-LC13 Pain in the arm/shoulder: 3 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Pain in the arm/shoulder: 6 month PSBRT0 (0 to 33)
EORTC QLQ-LC13 Pain in the arm/shoulder: 9 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Pain in the arm/shoulder: 12 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Pain in the arm/shoulder: 15 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Pain in the arm/shoulder: 18 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Pain in the arm/shoulder: 24 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Pain in other areas: Screening0 (0 to 100)
EORTC QLQ-LC13 Pain in other areas: 3 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Pain in other areas: 6 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Pain in other areas: 9 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Pain in other areas: 12 month PSBRT33 (0 to 100)
EORTC QLQ-LC13 Pain in other areas: 15 month PSBRT0 (0 to 67)
EORTC QLQ-LC13 Pain in other areas: 18 month PSBRT0 (0 to 100)
EORTC QLQ-LC13 Pain in other areas: 24 month PSBRT0 (0 to 100)

Adverse events

Collected over AEs will be recorded from consent until 100 days post the final infusion of nivolumab (average 12 cycles, typically 24 weeks, maximum 22 cycles/44 weeks). They will be systematically assessed at screening, each cycle of treatment (14 days), a safety follow-up visit (14 days after final infusion of nivolumab), and at each follow-up visit (3 month-, 6 month-, 9 month-, 12 month, 15 month-, 18 month- and 24 month-post SBRT) until participants reach the 100 days post the final infusion of nivolumab.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1 Tolerabilty6/31 (19.4%)18/31 (58.1%)30/31 (96.8%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventArm 1 Tolerabilty
Lung infectionInfections and infestations4/31
PneumonitisRespiratory, thoracic and mediastinal disorders3/31
AnemiaBlood and lymphatic system disorders1/31
Chest painCardiac disorders1/31
Heart failureCardiac disorders1/31
Myocardial infarctionCardiac disorders1/31
Adrenal insufficiencyEndocrine disorders1/31
Abdominal painGastrointestinal disorders1/31
ColitisGastrointestinal disorders1/31
DiarrheaGastrointestinal disorders1/31
Most frequent other events
Showing 10 of 127
Most frequent other events
EventArm 1 Tolerabilty
PruritusSkin and subcutaneous tissue disorders17/31
FatigueGeneral disorders16/31
CoughRespiratory, thoracic and mediastinal disorders14/31
PneumonitisRespiratory, thoracic and mediastinal disorders11/31
Lung infectionInfections and infestations9/31
HypothyroidismEndocrine disorders8/31
ConstipationGastrointestinal disorders8/31
DiarrheaGastrointestinal disorders8/31
DyspneaRespiratory, thoracic and mediastinal disorders8/31
Dry skinSkin and subcutaneous tissue disorders8/31

Baseline characteristics

Demographics for all registered and eligible patients recruited into the STILE study (n=31 patients)

Age, Continuous
Age, Continuous(years)Arm 1 Tolerabilty
Median73.0 (64.0 to 76.0)
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1 Tolerabilty
Female18
Male13
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1 Tolerabilty
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American2
White28
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Arm 1 Tolerabilty
United Kingdom31
Smoking status
Smoking status(Participants)Arm 1 Tolerabilty
Current smoker4
Ex-smoker25
Never smoker2
ECOG Performance Status
ECOG Performance Status(Participants)Arm 1 Tolerabilty
ECOG 07
ECOG 118
ECOG 26
Type of NSCLC
Type of NSCLC(Participants)Arm 1 Tolerabilty
Adenocarcinoma24
Not Otherwise Specified1
Squamous5
Stage at diagnosis
Stage at diagnosis(Participants)Arm 1 Tolerabilty
IA16
IB11
IIA2
IIB1

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Royal Marsden Hospital
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Mirsadraee S, Oswal D, Alizadeh Y, Caulo A, van Beek E Jr. The 7th lung cancer TNM classification and staging system: Review of the changes and implications. World J Radiol. 2012 Apr 28;4(4):128-34. doi: 10.4329/wjr.v4.i4.128. PubMed 22590666 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Aug 2024, 78 months.

Results were first posted in Jul 2026, 1 year 11 months after primary completion.

Of 123 non-industry phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 107. This study's 78 months is above that.

Counting every sponsor, half of 434 studies reached it within 62 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2017
First posted
Dec 26, 2017
StartActual
Feb 8, 2018
Primary completionActual
Aug 12, 2024
CompletionActual
Jun 26, 2025
Results first posted
Jul 17, 2026
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03383302
Responsible party
Sponsor
First posted
Dec 26, 2017
Start date
Feb 8, 2018
Primary completion
Aug 12, 2024
Completion
Jun 26, 2025
Results posted
Jul 17, 2026
Last update
Jul 17, 2026

Study contacts

Merina Ahmed
principal investigator · Royal Marsden NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion